Brief: Sana Biotechnology Says Six-Month Results Show Islet Cells Safe & Functional
23/06/2025 15:22
June 23 (Reuters) - Sana Biotechnology Inc SANA.O: SANA BIOTECHNOLOGY ANNOUNCES POSITIVE SIX-MONTH CLINICAL RESULTS FROM TYPE 1 DIABETES STUDY OF ISLET CELL TRANSPLANTATION WITHOUT IMMUNOSUPPRESSION SANA BIOTECHNOLOGY INC - STUDY SHOWS POTENTIAL TO TREAT TYPE 1 DIABETES WITHOUT IMMUNOSUPPRESSION SANA BIOTECHNOLOGY INC - SIX-MONTH RESULTS SHOW SANA'S ISLET CELLS SAFE AND FUNCTIONAL Source text: ID:nGNXbncjDK Further company coverage: SANA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sana Biotechnology
See all newsSana Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary
Sana Biotechnology Q2 adjusted loss narrows, beats estimates
Brief: Sana Biotechnology Q2 Adjusted EPS USD -0.13 Vs. IBES Estimate USD -0.15
Sana Biotechnology posts Q1 adjusted loss narrower than expected, extends cash runway
Brief: Sana Biotechnology Q1 Adjusted EPS USD -0.14 Vs. IBES Estimate USD -0.17